Table 2.
Clinical factors according to 18F-FDG-PET parameters
| Variable | Low TLG | High TLG | p-value |
|---|---|---|---|
| Age (yr) | |||
| < 50 | 31 (48.4) | 15 (45.5) | 0.78 |
| ≥ 50 | 33 (51.6) | 18 (54.5) | |
| Sex | |||
| Male | 20 (31.3) | 8 (24.2) | 0.47 |
| Female | 44 (68.7) | 25 (75.8) | |
| WHO pathology classification (except 1 unspecified patient) | |||
| I (keratinizing) | 2 (3.2) | 3 (9.1) | 0.46 |
| II (non-keratinizing) | 32 (50.8) | 17 (51.5) | |
| III (undifferentiated) | 29 (46.0) | 13 (39.4) | |
| T stage | |||
| T1-2 | 31 (48.4) | 13 (39.4) | 0.4 |
| T3-4 | 33 (51.6) | 20 (60.6) | |
| N stage | |||
| N0 | 6 (9.4) | 1 (3.0) | 0.25 |
| N1-3 | 58 (90.6) | 32 (97.0) | |
| TNM staging | |||
| III | 44 (68.7) | 16 (48.5) | 0.05 |
| IVa-b | 20 (31.3) | 17 (51.5) | |
| Whole tumor volume (mL) | 36.4 (4.6-133.4) | 78.3 (21.6-267) | < 0.001 |
| SUVmax for whole tumor | 10.7 (1.3-23.7) | 17.3 (8.4-38.7) | < 0.001 |
| MTV for whole tumor | 32.2 (7.8-85.4) | 68.7 (29.5-230.6) | < 0.001 |
Values are presented as number (%) or median (range). 18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; TLG, total lesion glycolysis for whole tumor; WHO, World Health Organization; TNM, tumor-node-metastasis; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume.